TG Therapeutics AI Stock Analysis
Want to see TGTX full AI Analyst Report?
TG Therapeutics (TGTX) AI Stock Analysis
TG Therapeutics
(NASDAQ:TGTX)
The score is driven primarily by improving fundamentals (rapid revenue growth and sustained profitability) and a strongly positive earnings update with raised guidance. Technicals also support the view with an established uptrend. The main constraint is valuation risk from a very high P/E and the remaining need to prove consistent cash conversion and stable profitability over time.
TG Therapeutics (TGTX) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $9.48B
- Dividend Yield
- ―
- Average Volume (3M)
- 1.92M
- Price to Earnings (P/E)
- 84.4
- Beta (1Y)
- 0.34
- Revenue Growth
- 68.78%
- EPS Growth
- -75.71%
- Country
- US
- Employees
- 399
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
TG Therapeutics Business Overview & Revenue Model
Company Description
Based in New York City and established in 1993, TG Therapeutics, Inc. is a biopharmaceutical company that has advanced to the commercial stage. Its core mission revolves around the acquisition, advancement, and marketing of novel therapeutic solution...
How the Company Makes Money
TG Therapeutics makes money primarily through net product revenue from sales of BRIUMVI in the United States. Revenue is generated when the company sells product to specialty distributors and other customers (e.g., specialty pharmacies), and recogniz...
TG Therapeutics Earnings Call Summary
The call was strongly positive, with record commercial performance, raised 2026 revenue guidance, sustained BRIUMVI clinical results, improving profitability, share repurchases, and multiple expansion opportunities across simplified IV dosing, subcutaneous administration, azer-cel, and additional indications. The company noted ongoing gross-to-net pressure, early-stage data and regulatory dependencies, but characterized the 340B exposure as limited and continued to describe its commercial and financial outlook as strong.
Q3-2026 Updates
Positive Updates
Negative Updates
Company Guidance
TG Therapeutics raised its full year global revenue guidance to $1 billion for 2026, including full-year U.S. BRIUMVI net product revenue guidance from $890 million to $905 million to a new range of $915 million to $920 million, reflecting more than $260 million for the fourth quarter; it also expects approximately $1 billion in total global revenue, including projected payments from its ex-U.S. partner. Full-year R&D and SG&A expenses, excluding stock-based comp, are expected to be in line with prior guidance of $450 million-$500 million. The company is targeting a potential approval of the consolidated IV initiation dose around mid-2027, with the impact expected to emerge in the latter part of the second half of 2027 and into 2028, while Phase III results for subcu BRIUMVI are expected around year-end or early 2027 and a potential commercial launch is targeted for 2028. The company has not given guidance for 2027 and expects minimal impact from 340B policy changes, with 340B representing maybe about 5% of its business.
TG Therapeutics Financial Statement Overview
Summary
Strong revenue scale-up and improved profitability (TTM revenue ~$897.8M, ~11.3% EBIT margin, ~82.7% gross margin) support a solid score. Offsetting this are profitability volatility (notably an unusually high 2025 net margin versus other periods) and historically inconsistent cash generation, with cash conversion still modest in the TTM period.
Income Statement
78PositiveBalance Sheet
70PositiveCash Flow
62Positive| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 897.76M | 616.29M | 329.00M | 233.66M | 2.79M | 6.69M |
| Gross Profit | 742.84M | 515.57M | 290.52M | 219.53M | 2.52M | 5.90M |
| EBITDA | 191.33M | 134.36M | 49.90M | 26.10M | -213.11M | -341.97M |
| Net Income | 106.06M | 447.18M | 23.38M | 12.67M | -223.81M | -348.10M |
Balance Sheet | ||||||
| Total Assets | 1.59B | 1.06B | 577.69M | 329.59M | 193.57M | 379.63M |
| Cash, Cash Equivalents and Short-Term Investments | 504.67M | 141.97M | 311.00M | 217.51M | 161.68M | 314.76M |
| Total Debt | 754.37M | 260.73M | 253.72M | 110.80M | 83.06M | 79.05M |
| Total Liabilities | 1.02B | 415.23M | 355.33M | 169.09M | 134.99M | 142.48M |
| Stockholders Equity | 572.13M | 648.02M | 222.36M | 160.50M | 58.59M | 237.15M |
Cash Flow | ||||||
| Free Cash Flow | 85.56M | -24.99M | -40.56M | -31.41M | -176.18M | -296.04M |
| Operating Cash Flow | 86.26M | -24.77M | -40.52M | -31.41M | -176.17M | -295.63M |
| Investing Cash Flow | -23.14M | 13.80M | -1.04M | -50.65M | -20.01M | -332.00K |
| Financing Cash Flow | 292.23M | -89.73M | 128.53M | 72.70M | -391.00K | 41.42M |
TG Therapeutics Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TGTX, the sentiment is Positive. The current price of 62.71 is above the 20-day moving average (MA) of 59.82, above the 50-day MA of 56.97, and above the 200-day MA of 45.71, indicating a bullish trend. The MACD of 2.29 indicates Negative momentum. The RSI at 59.16 is Neutral, neither overbought nor oversold. The STOCH value of 64.97 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TGTX.
TG Therapeutics Risk Analysis
TG Therapeutics disclosed 74 risk factors in its most recent earnings report. TG Therapeutics reported the most risks in the "Finance & Corporate" category.
Latest Risks Added
3 New RisksTG Therapeutics Peers Comparison
Overall Rating
ARQT79Outperform
PTGX72Outperform
TGTX72Outperform
KYMR60Neutral
IMVT53Neutral
LEGN52Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 79Outperform | $3.46B | 116.11 | 14.18% | ― | 60.00% | ― | |
| 72Outperform | $8.14B | 24.09 | 42.83% | ― | 163.69% | 574.89% | |
| 72Outperform | $9.48B | 84.45 | 17.62% | ― | 68.78% | -75.71% | |
| 60Neutral | $10.37B | -33.58 | -22.39% | ― | 133.77% | -0.64% | |
| 53Neutral | $6.87B | -12.91 | -63.01% | ― | ― | 9.82% | |
| 52Neutral | $3.12B | -1612.68 | -0.02% | ― | 49.73% | 98.75% | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| TGTX | TG Therapeutics | 62.71 | 32.26 | 105.94% | |
| PTGX | Protagonist Therapeutics Inc | 124.67 | 40.47 | 48.06% | |
| IMVT | Immunovant, Inc. | 33.21 | 10.42 | 45.72% | |
| ARQT | Arcutis Biotherapeutics Inc | 27.33 | 0.00 | 0.00% | |
| LEGN | Legend Biotech Corporation | 16.11 | -11.42 | -41.48% | |
| KYMR | Kymera Therapeutics, Inc. | 121.52 | 56.89 | 88.02% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 10, 2026
